In this Q&A, Marty Becker, DVM, Elite FFCP-V and Paul Bloom, DVM, DACVD, DABVP (Canine and Feline), Elite FFCP-III share ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

The global atopic dermatitis treatment market is on the cusp of remarkable expansion, with projections indicating a surge in ...

A recent study published in the Dermatology and Therapy journal confirmed the effectiveness and safety of upadacitinib, a ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, plans to begin testing ENV-294, its leading drug candidate developed to treat atopic ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...

For children with atopic dermatitis, early childhood stressful life events are associated with an increased risk for disease activity.